Skip to main content

MS news

Our news web pages include ground-breaking multiple sclerosis news and research from around the world. 

These news stories are taken from external sources and as such, MS-UK does not verify, endorse or accept responsibility for their content.

Some of these pages have been written for medical professionals and this can be reflected in the complexity of language and content.

Supporting you

We’re here to support you, whether you are awaiting a diagnosis of multiple sclerosis or have been living with the condition for years. 

Image of the MS-UK Helpline button graphic containing a link to the Helpline page

Image of the New Pathways magazine button graphic containing a link to the New Pathways magazine page


A prospective new method of treating patients with multiple sclerosis (MS) has been proposed by researchers of the Mainz University Medical Center in Germany working in cooperation with...

A study released at #ACTRIMS2018 has revealed that patients who experienced relapses after two courses of Lemtrada (alemtuzumab) showed improvement in relapse rate and disability progression after...

Germany recently informed the European Medicines Agency (EMA) that seven patients with multiple sclerosis (MS) had developed immune-mediated inflammation of the brain (encephalitis) during...

Eating fish at least once a week or eating fish one to three times per month in addition to taking daily fish oil supplements may be associated with a reduced risk of multiple sclerosis (MS),...

On Friday 23 February, the United Patients Alliance gathered for another peaceful protest outside the House of Parliament while the second reading of the Emily Brice bill took place.

...

In recent years there has been a substantial increase in the use of medical cannabis, particularly with the aging population. In a recent study, titled 'Epidemiological characteristics, safety and...

A recent study, published in the journal Neurology assessed foetal risk after pregnancy exposure to natalizumab (Tysabri) in women with multiple sclerosis (MS). The Italian study specifically...

NHS Scotland has accepted cladribine (Mavenclad) as a treatment option for people with highly active multiple sclerosis (MS) living in Scotland.

The Scottish Medicines Consortium (SMC),...

Sandoz, a Novartis division, has announced US Food and Drug Administration (FDA) approval and launched a 40 mg/ml dose of Glatopa, a glatiramer acetate injection.

Glatopa 40 mg/ml is FDA-...

When the body attacks its own healthy tissues in an autoimmune condition, peripheral nerve damage disable people and causes persistent neuropathic pain when insulation on healing nerves doesn't...

Pages

Live Chat Software by Click4Assistance UK